Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

The firm currently has a $70.00 price objective on the stock ... average price is $19.74. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $1,170.24.

as evidenced by the stock’s significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix Pharmaceuticals and offer a new treatment option ...

we considered the stocks with the highest day change performance. A scientist in a lab coat working with a microscope, researching a biopharmaceutical solution. Shares of Tonix Pharmaceuticals ...

Investors have responded positively to the news, as evidenced by the stock’s significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix ...